Danske Bank’s Pacira BioSciences PCRX Stock Holding History

Danske Bank’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-223	Closed	-$5.33K	–	1546
2025 Q2	$5.33K	Sell	223 -61,104	-100%	-$1.54M	﹤0.01%	1343
2025 Q1	$1.52M	Buy	+61,327	New	+$1.47M	﹤0.01%	748

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Danske Bank's PCRX Position: Q3 2025 in Review

Danske Bank sold out of Pacira BioSciences (PCRX) in Q3 2025, closing a stake of 223 shares — an estimated $5.33K sold.

Danske Bank first reported a position in PCRX in Q1 2025 and held it in 2 quarters. The position peaked at $1.52M in Q1 2025. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2025.

Danske Bank reported no remaining Pacira BioSciences position as of Q3 2025 after selling out during the quarter.
Danske Bank sold 223 Pacira BioSciences shares in Q3 2025, an estimated $5.33K.
Danske Bank first reported a position in Pacira BioSciences in Q1 2025 and held it in 2 quarters.
Danske Bank's Pacira BioSciences position peaked at $1.52M in Q1 2025.
239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2025.

Based on Danske Bank's 13F filing for Q3 2025, filed 13 Nov 2025.